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Release exponentAbstract Purpose: To design an oral mucoadhesive tablet of ceﬁxime trihydrate using response
surface methodology (RSM), and further to investigate the inﬂuence of formulation variables on
drug release, and mucoadhesive strength.
Methods: Tablets were prepared by direct compression method. A 23 factorial design was used to
identify key independent variables affecting the drug release and mucoadhesive strength of formu-
lation. The experimental data were analyzed statistically and the adequacy of ﬁtted response was
established through analysis of variance (ANOVA). The mechanism of drug release was investi-
gated in detail by ﬁtting the data to various kinetic models using PCP-DISSO V3 program.
Results: Batch M3 showed the potential to retard the drug release and possessed signiﬁcant
mucoadhesive strength of 32.60 ± 0.1025 g. ANOVA results were substantiated by the Pareto anal-
ysis (p value <0.05) suggesting that the amount of carbopol (CP) 974P was the major factor affect-
ing the studied responses. All the experimental batches followed either Higuchi or Peppas model
and had release exponent (n) within 0.221–0.874. A distinct shift from ﬁckian diffusion to anoma-
lous transport of drug was noted with an increase in amount of CP 974P.
Conclusion: Ceﬁxime trihydrate can be effectively formulated as an oral controlled release mucoad-
hesive tablet using RSM, and it is possible to achieve adequate mucoadhesive strength and the
desired release proﬁle with the optimum combination of polymers.
 2016 Publishing services provided by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Ceﬁxime trihydrate, an orally active third generation cephalos-
porin antibiotic, is widely used for treatment of urinary tract
infection (UTI), upper and lower respiratory tract infection,
Table 1 Composition of ceﬁxime trihydrate mucoadhesive
tablets.*
Ingredient Amount (mg)
Ceﬁxime trihydrate 50–100 mg
HPMC K4M 60–100 mg
Carbopol 974P 60–100 mg
Magnesium stearate 3 mg
Microcrystalline cellulose (Avicel)
Dibasic calcium phosphate dihydrate
30 mg
q.s 350 mg
* q.s indicates quantity sufﬁcient.
228 J. Manwar et al.acute otitis media, and Gonococcal urethritis.1 On an oral
administration it gets slowly and incompletely absorbed from
GIT. Here, it is necessary to realize that an ionic charge on
ceﬁxime creates difﬁculty to cross mucosal membrane of the
intestine, resulting in poor bioavailability of 40–50%.2,3
Mucoadhesive polymers are known to increase residence time
of drug with an absorbing tissue.4,5 Also, they are able to par-
tially neutralize the ionic charge on drug molecule.2,6 Thus, an
improved transit and charge neutralization with mucoadhesive
polymer was thought signiﬁcant while developing ceﬁxime tri-
hydrate mucoadhesive tablets. In the present work, we have
screened HPMC K4M, K15M, K100M, and carbopol (CP)
974P for the selection of most appropriate matrix for the drug.
The viscosity and the concentration of polymer are the two
prime factors that affect release of drug both kinetically and
mechanistically.7,8 Moreover, combined usage of HPMC and
carbopol has been reported by several researchers in modulat-
ing drug release.9–11 Nevertheless, the marked difference in
their architectural properties, especially the orientation of
polymer chains, was expected to inﬂuence the rigidity of result-
ing matrix affecting the kinetics of drug release.12,13 Thus, an
in-depth investigation on the drug release mechanism from
such matrices was thought signiﬁcant. Here, in order to estab-
lish mechanism of drug release from an engineered matrix sys-
tem based on combination of polymers, we performed a
detailed kinetic study using PCP-DISSO V3 program. The
release data was ﬁtted to various kinetic models using residual
sum of squares method, and various kinetic parameters such as
release exponent (n), rate constant (k), and correlation coefﬁ-
cient (r) were investigated.
As described earlier by Kumbhar and Pokharkar, response
surface methodology (RSM) and factorial designs are the valu-
able tools in identiﬁcation of independent formulation vari-
ables inﬂuencing the responses.14,15. Here, in designing a
robust matrix with the desired properties, we used 23 (three
factors-two levels) factorial design, and further studied the
inﬂuence of independent variables on the mucoadhesive
strength and % drug release. The obtained data were analyzed
by second order polynomials and the adequacy of ﬁtted
response was established statistically through analysis of vari-
ance (ANOVA). Additionally, the Pareto analysis was
employed to identify the most signiﬁcant variable affecting
the studied responses. The designed system was further studied
for its stability as per ICH guidelines.16 Thus, in brief, here we
designed a robust matrix system based on combination of
polymers using a response surface methodology (RSM) for
an oral delivery of ceﬁxime trihydrate, and further studied its
release behavior, bioadhesion, and the stability aspects.2. Experimental
2.1. Materials
Ceﬁxime trihydrate was obtained from Lupin laboratory Pune,
India. Various grades of hydroxypropyl methylcellulose
(HPMC K4M, K15M, and K100M) were obtained from Cipla
Ltd., India. CP 974P was a generous gift from BF Goodrich,
USA. Microcrystalline cellulose (Avicel) was purchased from
IPCA laboratory, Gujarat, India. Buffer reagents, dibasic cal-
cium phosphate, and magnesium stearate was purchased from
Loba Chemie, India. All other chemicals were of analytical
grade and used as received.
2.2. Methods
2.2.1. Screening of components and preformulation study
Mucoadhesive polymers such as HPMC (K4M, K15M and
K100M) and CP 974P were evaluated for viscosity, % water
sorption, shear stress and adhesion force measurement.
2.2.2. Preparation of cefixime trihydrate mucoadhesive tablets
Tablets were prepared by direct compression method. Table 1
depicts the composition of different mucoadhesive formula-
tions. The drug, polymers and excipients were accurately
weighed on an electronic balance and were mixed properly in
a mortar. The well mixed powder was compressed using Cad-
mach tablet pressing machine at 100 kg/cm2 with compression
time of 1 min.
2.2.3. Effect of variables
A 23 factorial design was used to study the effect of formula-
tion variables on the performance and characteristics of
mucoadhesive tablet. The amounts of drug (X1), HPMC
K4M (X2) and CP 974P (X3) were selected as the three inde-
pendent formulation variables. Percent drug release (Y1),
and mucoadhesive strength (Y2) were selected as the depen-
dent response variables. Amount of magnesium stearate
(3 mg) and microcrystalline cellulose (30 mg) was kept con-
stant in all the batches. Table 2 depicts values of all variables
and codes of the different batches.
2.2.4. Tablet assay and physical evaluation
The tablets were assayed for drug content using methanol as
extracting solvent, and the samples were analyzed at 288 nm
using dual beam UV spectrophotometer (Jasco, Japan).
Tablets were also evaluated for weight variation (n = 10),
hardness (n = 6), thickness (n = 10) and friability (n = 20).
2.2.5. Ex-vivo mucoadhesion studies
(a) Selection of model mucosal surface
In bioadhesion study it is important to use uniform surfaces
that allow the formation of reproducible adhesive bonds.17 In
this work, we used sheep intestine as model mucosal surface
for bioadhesion. Sheep intestine was obtained from local
slaughterhouse and kept in a Tyrode solution [quantitative
composition (g/L): sodium chloride (8 g), potassium chloride
(0.2 g), calcium chloride dihydrate (0.134 g), sodium bicarbon-
Table 2 Experimental design depicting formulation variables and the obtained responses for the studied batches.
Batch code Formulation variables (X) Responses (Y)
X1: Amount of drug (mg) X2: K4M (mg) X3: CP 974P (mg) Y1:% Drug release (12 h) Y2: Mucoadhesive strength (g)
M1 50 (1) 60 (1) 60 (1) 73.24 ± 0.14 18.23 ± 0.1623
M2 50 (1) 60 (1) 100 (+1) 68.06 ± 0.27 21.48 ± 0.1012
M3 50 (1) 100 (+1) 100 (+1) 54.55 ± 0.49 32.60 ± 0.1025
M4 50 (1) 100 (+1) 60 (1) 84.56 ± 2.4 16.78 ± 0.1529
M5 100 (+1) 60 (1) 100 (+1) 75.50 ± 0.63 19.17 ± 0.1845
M6 100 (+1) 60 (1) 60 (1) 98.39 ± 0.81 14.80 ± 0.1227
M7 100 (+1) 100 (+1) 60 (1) 95.20 ± 0.70 16.11 ± 0.1317
M8 100 (+1) 100 (+1) 100 (+1) 66.61 ± 3.2 24.60 ± 0.1025
A value in parentheses indicates coded level.
Optimizing oral mucoadhesive tablet of ceﬁxime trihydrate 229ate (1 g), sodium dihydrogen phosphate (0.05 g), and glucose
(1 g)] at 4 C.
(b) Fabrication of assembly
Mucoadhesion studies were conducted using a modiﬁcation
of the assembly described earlier by Madgulkar et al.18 Brieﬂy,
the sheep intestine was cut into strips so that its mucosal
side gets exposed and kept in a tyrode solution. Mucosal
surface facing upward side tied to support. The tablet was
kept on mucosal surface under the constant weight of 5 g for
1 min. Mucoadhesive strength was measured by the total
weight in grams required to detach the tablet from the mucosal
surface.
2.2.6. In-vitro drug release studies
The in-vitro drug release study was carried out for all the
experimental batches using standard USP dissolution test
apparatus (DA-6D) at 37 ± 2 C and 50 rpm. The study was
performed with USP II paddle method (Apparatus II) using
saline phosphate buffer (PBS pH 7.4) as a dissolution medium.
The release kinetic study was performed using PCP DISSO V3
program (Poona College of Pharmacy, Pune), based on the fol-
lowing equations:
Higuchimatrix : %R ¼ kmt0:5 ð1Þ
Korsmeyer Peppas : %R ¼ kptn ð2Þ
Zero order : %R ¼ k0t ð3Þ
First order : log % unreleased ¼ k1t=2:303 ð4Þ
Hixson-Crowell : ð% unreleasedÞ1=3 ¼ kht ð5Þ
where% R is percent drug release; t is time; k0, k1, km, kp, and
kh are the rate constants for zero order, ﬁrst order, Higuchi-
matrix, Korsmeyer–Peppas and Hixson–Crowell respectively.
‘‘n” indicates release exponent.
2.2.6. Data analysis and validation of optimization model
The responses (% drug release and mucoadhesive strength)
were investigated by a two-way ANOVA-based factorial anal-
ysis. An RSM computation for the current optimization was
performed using STATISTICA version 8 (Stat-soft, Inc.,
USA). The data were ﬁtted to the second order polynomial
equation (Eq. (6)), and adequacy of a ﬁtted response waschecked by analysis of variance (ANOVA). The statistical
signiﬁcance was set to p< 0.05, and the generated response
surfaces, contour plots, residual plots, and Pareto charts were
studied.
Y ¼ b0 þ b1X1þ b2X2þ b3X3þ b12X1X2þ b13X1X3
þ b23X2X3 ð6Þ
where Y= dependent variable (response variable), X1, X2,
and X3 = independent formulation variables, ß0 = intercept,
ß1, ß2, ß3 = linear regression coefﬁcients, ß12, ß13, ß23 = inter-
action coefﬁcients.
2.2.7. Stability study
Stability testing of an optimized formulation (Batch M3) was
carried out at 40 ± 2 C and 75 ± 5% RH for the period of
3 months as per ICH guidelines.16 The evaluation parameters
for stability study included drug content, mucoadhesive
strength and the percent drug release.
3. Result and discussion
3.1. Screening of components and preformulation study
The objective of the preliminary work was to select an appro-
priate polymer matrix and further to establish the optimum
formulation parameters. Among the screened polymers (data
not shown) HPMC K4M and CP 974P had viscosities (cPs)
of 3557 and 29,690, % water sorption of 82 and 97, shear stress
(g) of 39.70 and 51.8, and adhesive strength (g) of 46.2 and
58.2, respectively. CP 974P had considerably high viscosity,
as on dispersion the polymer begin to hydrate and partially
uncoil. Moreover, upon neutralization it ionizes generating
negative charges along the backbone of the polymer.19 These
negative charges in close proximity to one another was
expected to result in an electrostatic repulsion causing the
polymer to uncoil more creating extended three dimensional
structure. Here, it is necessary to realize that the viscosity of
the polymer inﬂuences the swelling process affecting the drug
release behavior.20 Also, to note that the carboxyl (–COOH)
group of CP 974P can encourage ionic and hydrogen bond
interaction with mucin chain resulting in an improved adhe-
sion21. Thus, HPMC K4M and CP 974P were found optimum
with respect to swelling and adhesion and hence selected for 23
factorial design.
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3.2.1. Effect of formulation variables on % drug release
Table 2 summarizes the obtained% drug release (12 h) from all
the experimental batches as a function of formulation vari-
ables. The estimated effects and the interaction coefﬁcients
for the response Y1 (% drug release) are presented in Table 3.
As can be seen from negative regression coefﬁcients for X2 and
X3 (Table 3), both the polymer used had an inverse relation
with the % drug released. However, by considering a high
magnitude of X3, amount of CP 974P was identiﬁed as a major
factor retarding the drug release. Surface response curves and
contour plots assist to better understand the relationship
between independent and dependent variables.22–24
Fig. 1A and B respectively depicts the surface and contour plot
of % drug released (Y1) as a function of formulation variables
(X2 and X3). As evident in Fig. 1, Y1 decreases steeply with an
increase in amounts of CP 974P (X3) from 60 to 100 mg. In
this regard, a reduction in regions of low microviscosity and
the closing of micropores in the swollen tablets was thought
signiﬁcant in retarding the drug release.12 The adequacy of
the ﬁtted response (Y1) was established through ANOVA
(Table 4). As shown in Table 4, among the studied variables,
amount of CP 974P (X3) had a statistically signiﬁcant (p-
value 0.029510) inﬂuence on response Y1. Moreover, in order
to ensure the signiﬁcance of X3, we considered the Pareto anal-
ysis. Here, it is necessary to realize that the Pareto analysis is a
statistical technique that assists to identify the most important
variable affecting the studied response.22–25 Fig. 2A depicts the
Pareto chart summarizing the standardized effect estimates
(absolute value) for the response Y1 as a function of formula-
tion variables. As evident in Fig. 2A, among the studied vari-
ables, X3 had an effect of 5.69158 and was statistically
signiﬁcant (p-value <0.05). Thus, the ﬁndings of the Pareto
analysis was well in agreement with ANOVA results suggesting
that amount of CP 974P (X3) was the major factor inﬂuencing
the response Y1. Moreover, a good correlation (r2 = 0.9627)
between observed and predicted residuals of response Y1
(Fig. 2B) substantiated the signiﬁcance of employed experi-
mental design. Here, it is also necessary to consider that CP
974P is a high molecular weight cross-linked polymer of acrylic
acid which is polymerized in ethyl acetate and treated with (1–
3%) potassium.26 The presence of potassium in CP 974P can
inﬂuence the swelling of the polymer by shielding the repulsion
between negatively charged carboxylic (–COOH) groups, sub-
sequently affecting the rate of drug release. On the other hand,
unlike carbopol polymer, drug release from HPMC matrices is
governed by the formation of gel layer with longer diffusionalTable 3 Effect estimates and the interaction coefﬁcients for respon
R2 = 0.9627; Adj:0.86945; MS Residual = 28.98556
Factor Eﬀect Std.Err. t(2) p 9
Mean/Interc. 77.0137 1.903469 40.45968 0.000610 68
X1 13.8225 3.806939 3.63087 0.068187 2
X2 3.5675 3.806939 0.93710 0.447630 1
X3 21.667 3.806939 5.69158 0.029510 3
X1X3 4.0725 3.806939 1.06976 0.396722 2
X2X3 7.6325 3.806939 2.00489 0.182839 2path.27 This could cause a decrease in effective diffusion coef-
ﬁcient of drug and therefore reduction in drug release rate.
Thus, as evidenced by signiﬁcant negative regression coefﬁ-
cient of X2X3 (Table 3), both the polymer retarded the drug
release from the tablet matrix and the amount of polymer
was the main determinant of the drug release proﬁle. Here,
RSM enabled us to identify the optimum polymer blend to
achieve the desired drug release from an engineered matrix
tablet.
3.2.2. Effect of formulation variables on mucoadhesive strength
Table 2 summarizes the obtained mucoadhesive strength for all
the experimental batches as a function of formulation vari-
ables. The estimated effects and the interaction coefﬁcients
for the response Y2 (mucoadhesive strength) are presented in
Table 5. As can be seen from positive regression coefﬁcient
for X2 and X3 (Table 5), both the polymer used increased
the mucoadhesive strength of the formulation. This was also
evident in Fig. 3A and B, where, the steep increase in response
Y2 (mucoadhesive strength) was noted with an increase in
amounts of either polymer CP 974P and HPMC K4M from
60 to 100 mg. Here, an increase in response with the amount
of polymers could be the outcome of availability of more adhe-
sive sites and polymer chains for interpenetration with
mucin.28 Among the studied batches, batch M3, comprising
of ceﬁxime (50 mg), CP 974P (100 mg) and HPMC K4M
(100 mg) showed the maximum mucoadhesive strength of
32.60 ± 0.1025 g. Table 6 summarizes the ANOVA results
for the ﬁtted response (Y2) as a function of formulation vari-
ables. The result (Table 6) clearly shows that the variable X3
(amount of CP 974P) had the statistically signiﬁcant (p-value
0.037061) inﬂuence on response Y2. In this regard, an
improved response could be correlated with the presence of
sufﬁcient number of carboxylic groups (–COOH) in CP 974P
favoring the ionic and hydrogen bond interaction with mucin
chains and thereby bioadhesion.12,21 The results of ANOVA
study was further complemented by the Pareto analysis
(Fig. 4A), wherein among the studied variables, X3 (amount
of CP 974P) showed maximum effect of 5.048974 and had sta-
tistical signiﬁcance (p-value <0.05). Besides, a good correla-
tion (r2 = 0.9676) was noted between observed and predicted
residuals of response Y2 as a function of formulation variables
(Fig. 4B).
3.3. Tablet assay and physical evaluation
The drug content of various experimental batches varied
between 98.39 ± 0.15% and 100.7%± 0.15%, tablet weightsse Y1 (% drug release).
5.% Cnf.Limt +95.% Cnf.Limt Coeﬀ. Std.Err. Coeﬀ.
.8238 85.20372 77.0137 1.903469
.5574 30.20243 6.9113 1.903469
9.947 12.81243 1.7837 1.903469
8.047 5.28757 10.833 1.903469
0.452 12.30743 2.0363 1.903469
4.012 8.74743 3.8163 1.903469
Figure 1 Estimated response surface (A) and contour plot (B) for % drug released (Y1) as a function of formulation variables (X2 and
X3).
Table 4 ANOVA statistical analysis of response Y1 (% drug release).
Evaluated factors and their interactions Sum of squares (SS) Degrees of freedom (DF) Mean square (MS) F-value p-value*
X1 382.123 1 382.1230 13.18322 0.068187
X2 25.454 1 25.4541 0.87817 0.447630
X3 938.961 1 938.9611 32.39410 0.029510
X1X3 33.171 1 33.1705 1.14438 0.396722
X2X3 116.510 1 116.5101 4.01959 0.182839
Error 57.971 2 28.9856
Total SS 1554.190 7
* Considered statistically signiﬁcant for p-value <0.05.
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had thickness between 2.30 ± 0.19 and 2.45 ± 0.23 mm, hard-
ness between 5.9 ± 0.23 and 7.5 ± 0.23 kg/cm2, and friability
within 0.25 ± 0.17 and 0.47 ± 0.13%.
3.4. In-vitro drug release and release kinetic study
We performed release study to probe the drug release proﬁle,
and further to establish the mechanism of drug release from
an engineered matrix tablet of ceﬁxime trihydrate. Fig. 5
depicts the comparative drug release proﬁle from all the exper-
imental batches. The release proﬁle (Fig. 5) demonstrated that
all the batches had biphasic release behavior with an initial
drug release of 30–60% at the end of ﬁrst six hours followed
by a slow release phase. Among the studied batches, batch
M3 showed the higher potential to retard the drug release.
The average drug release (% R), % dissolution efﬁciency
(DE) & mean dissolution time (MDT) is summarized in
Table 7. In order to investigate mechanism of drug release
from an engineered matrix tablets data modeling was
performed by ﬁtting the data into various kinetic models likezero order, ﬁrst order, Higuchi-matrix, Korsmeyer–Peppas,
and Hixson–Crowell. The results of model ﬁtting are depicted
in Fig. 6 and the model ﬁtting data computed using residual
sum of squares method are summarized in Table 8. Moreover,
the obtained kinetic parameters (k, r and n) are shown in
Table 9. Based on the higher values for correlation coefﬁcients
(Table 9), batches. M4, M7 and M8 comprising of a higher
amount of HPMC K4M followed the Higuchi model, and
had release exponent (n) within 0.221–0.407. This (n< 0.5)
strongly indicated ﬁckian diffusion as a predominant mecha-
nism of drug release from these batches. In contrast to this,
the batches M1, M2, M3, M5 and M6 comprising of a signif-
icant amount of CP 974P followed the Peppas release kinetics,
and had release exponent within 0.514–0.874. This (n> 0.5)
strongly indicated an anomalous type of drug release from
these batches.29 Here, both the ﬁckian diffusion through the
hydrated matrices, and a polymer chain relaxation/ erosion
was considered to be an important mechanism governing the
drug release from engineered matrices.30,31 The noted shift in
the drug release from ﬁckian diffusion to anomalous transport
was thought to be the inﬂuence of amount of CP 974P on the
rigidity of matrix.
Figure 2 Pareto analysis (A) and observed vs predicted residual plot (B) for response Y1 (% drug released) as a function of formulation
variables.
Table 5 Effect estimates and the interaction coefﬁcients for response Y2 (mucoadhesive strength).
R2 = 0.9676; Adj: 85215; MS Residual = 4.999213
Factor Eﬀect Std. Err. t(2) p 95.% Cnf.Limt +95.% Cnf.Limt Coeﬀ. Std. Err. Coeﬀ.
Mean/Interc 20.4712 0.790507 25.8963 0.00148 17.0700 23.8725 20.4712 0.790507
X1 3.60250 1.581014 2.2786 0.15034 10.405 3.20006 1.8012 0.790507
X2 4.10250 1.581014 2.59485 0.12193 2.7001 10.9050 2.05125 0.790507
X3 7.98250 1.581014 5.04897 0.03706 1.1799 14.7850 3.99125 0.790507
X1X3 1.55250 1.581014 0.9819 0.42965 8.3551 5.25006 0.7762 0.790507
X2X3 4.17250 1.581014 2.63913 0.118575 2.6301 10.9750 2.08625 0.790507
Figure 3 Estimated response surface (A) and contour plot (B) for mucoadhesive strength (Y2) as a function of formulation variables (X2
and X3).
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Table 6 ANOVA statistical analysis of response Y2 (Mucoadhesive strength).
Evaluated factors and their interactions Sum of squares (SS) Degrees of freedom (DF) Mean square (MS) F-value p-value*
X1 25.9560 1 25.9560 5.19202 0.150345
X2 33.6610 1 33.6610 6.73326 0.121939
X3 127.4406 1 127.4406 25.49214 0.037061
X1X3 4.8205 1 4.8205 0.96425 0.429654
X2X3 34.8195 1 34.8195 6.96500 0.118575
Error 9.9984 2 4.9992
Total SS 236.6961 7
* Considered statistically signiﬁcant for p-value <0.05.
Figure 4 Pareto analysis (A) and observed vs predicted residual plot (B) for response Y2 (mucoadhesive strength) as a function of
formulation variables.
Table 7 % Release (average with % dissolution efﬁciency & mean dissolution time).
Sr. No. Time Avg. % R SD SE-mean % DE MDT RSD
1 0 0.000 0.00 0.00 0.00 0.00 0.00
2 1 15.268 3.39 1.39 7.63 0.50 22.23
3 2 25.637 2.87 1.17 14.04 0.90 11.19
4 3 33.255 1.71 0.70 19.18 1.27 5.14
5 4 41.918 4.85 1.98 23.78 1.73 11.57
6 5 49.573 6.35 2.59 28.17 2.16 12.81
7 6 57.951 9.71 3.96 32.44 2.64 16.75
8 8 63.700 10.68 4.36 39.53 3.03 16.77
9 10 70.551 13.09 5.34 45.05 3.61 18.55
10 12 76.162 14.15 5.78 49.77 4.16 18.58
Optimizing oral mucoadhesive tablet of ceﬁxime trihydrate 2333.5. Stability study
The stability studies of Batch M3 demonstrated insigniﬁcant
changes in the stability parameters (p-value <0.05). The drug
content was found to be 99.97 ± 0.14%, 99.67 ± 0.19% and
99.13 ± 0.23% at the end of 30, 60 and 90 days respectively
at 40 C/75%RH. The mucoadhesive strength was found to
be 32.60 ± 0.1025 g, 32.41 ± 0.1325 g and 32.37 ± 0.1715 g
at the end of 30, 60 and 90 days respectively, at 40 C/75%
RH. The % drug release was found to be 54.55 ± 0.49,54.98 ± 0.29 and 55.21 ± 0.37% at the end of 30, 60 and
90 days respectively, at 40 C/75%RH. Thus, the accelerated
storage conditions (40 C/75%RH) did not result in signiﬁcant
changes in the evaluation parameters ensuring the stability of
an engineered matrix tablets.
4. Conclusion
In this work, we successfully designed a robust matrix tablet
based on a combination of a linear (HPMC) and cross-
Figure 5 Comparative in vitro drug release proﬁles from
experimental batches using saline phosphate buffer (PBS, pH
7.4) as a dissolution medium.
Figure 6 Average drug release depicting various kinetic models.
Table 8 Model ﬁtting by Residual sum of squares method.
Release model
Zero 1st order Matrix Peppas Hix. Crow.
Sr. No. Time Avg. % R SD 959 53 121 98 187
1 0 0.000 0.00 0.000 0.000 0.000 – 0.000
2 1 15.268 3.39 57.788 6.698 42.947 0.944 22.535
3 2 25.637 2.87 106.215 3.557 27.269 0.000 28.746
4 3 33.255 1.71 105.222 0.027 20.612 0.035 15.679
5 4 41.918 4.85 126.690 0.003 2.970 2.286 18.586
6 5 49.573 6.35 126.448 0.116 0.609 7.735 18.770
7 6 57.951 9.71 142.959 5.201 20.255 27.025 32.783
8 8 63.700 10.68 5.636 6.248 3.923 0.001 0.437
9 10 70.551 13.09 37.277 13.512 2.395 10.622 13.636
10 12 76.162 14.15 250.461 17.526 0.328 49.695 35.344
Table 9 Release kinetic parameters.
Batch code Drug release model
Zero order First order Higuchi-matrix Peppas–Korsmeyer Hixson-Crowell
r k0 r k1 r km r kp n r kh
M1 0.8919 7.7552 0.9657 0.1274 0.9652 22.0760 0.9817 12.3953 0.527 0.9476 0.0355
M2 0.8566 6.5409 0.9646 0.0961 0.9901 18.7846 0.9975 18.2923 0.740 0.9406 0.0279
M3 0.7063 6.0425 0.8554 0.0834 0.9838 17.6385 0.9979 19.2309 0.657 0.8141 0.0248
M4 0.9537 7.9711 0.9869 0.1435 0.9979 22.4395 0.9840 17.2142 0.221 0.9937 0.0384
M5 0.8289 8.2199 0.9465 0.1402 0.9773 23.6821 0.9974 19.2874 0.874 0.9188 0.0385
M6 0.9679 9.1909 0.9013 0.2393 0.9697 25.7194 0.9944 13.9143 0.514 0.9776 0.0530
M7 0.9644 9.0370 0.9604 0.2041 0.9985 25.3179 0.9852 13.6461 0.321 0.9938 0.0492
M8 0.7660 7.2783 0.9177 0.1117 0.9959 21.1325 0.9863 21.1839 0.407 0.8790 0.0320
‘‘r” indicates correlation coefﬁcients, k0, k1, km, kp, and kh indicate rate constants for zero order, ﬁrst order, Higuchi-matrix, Peppas–Korsmeyer
and Hixson–Crowell respectively. ‘‘n” indicates release exponent.
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Optimizing oral mucoadhesive tablet of ceﬁxime trihydrate 235linked (Carbopol) polymer for the oral administration of ceﬁx-
ime trihydrate. ANOVA based factorial analysis enabled iden-
tiﬁcation of key formulation variables inﬂuencing the
mucoadhesive strength and the% drug release. Pareto analysis
substantiated ANOVA results conﬁrming that the amount of
CP 974P was the most signiﬁcant variable (p value <0.05)
affecting the responses. Batch M3 showed the potential to
retard the drug release and possessed signiﬁcant mucoadhesive
strength. The amount of either polymer used was crucial and
reﬂected through the distinct shift in the release behavior from
ﬁckian diffusion to anomalous transport. Moreover, the
tablets were found stable with respect to evaluation parameters
as per ICH guidelines. Finally, it could conclude that Ceﬁxime
trihydrate can be effectively formulated as an oral controlled
release mucoadhesive tablet using response surface methodol-
ogy, and it is possible to achieve adequate mucoadhesive
strength and the desired release proﬁle with the optimum com-
bination of HPMC K4M and CP 974P.
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